Vanguard Global Advisers
VIR icon

Vanguard Global Advisers’s Vir Biotechnology VIR Stock Holding History

Vanguard Global Advisers’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$536K Buy
52,590
+2,266
+5% +$21.6K ﹤0.01% 2070
2026
Q1 		$451K Buy
+50,324
New +$401K ﹤0.01% 2092

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Global Advisers's VIR Position: Q2 2026 in Review

Vanguard Global Advisers increased its Vir Biotechnology (VIR) stake by 4.5% in Q2 2026, buying an estimated $21.6K and bringing the position to 52,590 shares worth $536K. The position accounts for ﹤0.01% of the portfolio, ranked #2070.

Vanguard Global Advisers first reported a position in VIR in Q1 2026 and has held it in 2 quarters since. 235 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Vanguard Global Advisers held 52,590 shares of Vir Biotechnology worth $536K as of Q2 2026.
  • Vanguard Global Advisers bought 2,266 Vir Biotechnology shares in Q2 2026, an estimated $21.6K.
  • Vir Biotechnology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2070 holding.
  • Vanguard Global Advisers first reported a position in Vir Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 235 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.